WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 23, 779-789. Review Article ISSN 2277–7105

REGULATORY ASPECTS AND DOSSIER FILING FOR GENERIC PRODUCTS IN MIDDLE EAST COUNTRIES

A. Venkateswarlu*, M. V. Nagabhushanam and M. Beena Devi

Department of Pharmaceutical Regulatory Affairs, Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India-522002.

Article Received on
14 October 2024,

Revised on 03 Nov. 2024,
Accepted on 24 Nov. 2024

DOI:10.20959/wjpr202423-34821

***Corresponding Author**
A. Venkateswarlu
Department of Pharmaceutical Regulatory Affairs, Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh, India-522002.

ABSTRACT

The regulatory approval and dossier filing for generic products in Middle Eastern countries involve adhering to diverse frameworks and addressing country-specific requirements. While efforts like the GCC-DR streamline processes across Gulf Cooperation Council countries, manufacturers must also meet localized demands such as Arabic labeling, Zone IVb stability studies, and compliance with specific packaging standards. The preparation of a Common Technical Document (CTD), supported by robust bioequivalence studies and GMP-compliant production, is central to the approval process. Despite challenges like regulatory variability and prolonged timelines, the region presents significant opportunities for generic manufacturers due to its growing demand for affordable pharmaceuticals and healthcare services.

KEYWORDS: Middle Eastern countries, Generic products, Common Technical Document (CTD).

1. INTRODUCTION[1-3]

The regulatory framework and dossier filing requirements for generic products in Middle Eastern countries vary across the region due to the diverse regulatory landscapes and differing healthcare policies. Below is a detailed explanation of the regulatory aspects and dossier filing processes for generic drug products in key Middle Eastern countries.

1. Regulatory Framework

The regulatory authorities in the Middle East oversee the approval, quality assurance, and market entry of generic drugs to ensure patient safety and compliance with international standards. Key regulatory authorities include.

- **Gulf Cooperation Council (GCC)**
  - Comprises Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE.
  - GCC countries often align their requirements under the **GCC-DR (GCC Drug Registration) program**, but individual countries also maintain independent regulatory systems.

- **Other Middle Eastern Countries**
  - **Egypt:** Managed by the Egyptian Drug Authority (EDA).
  - **Jordan:** Overseen by the Jordan Food and Drug Administration (JFDA).
  - **Lebanon:** Regulated by the Ministry of Public Health.
  - **Iran:** Regulated by the Food and Drug Administration of Iran.

2. General Requirements for Generic Products

Generic products must meet certain criteria for approval in Middle Eastern countries.

1. **Bioequivalence Study**
   - Demonstrates that the generic product is pharmaceutically equivalent and bioequivalent to the reference product.
   - Often conducted as per **ICH guidelines** or **WHO standards**.

2. **Good Manufacturing Practice (GMP) Compliance**
   - Manufacturing facilities must comply with GMP standards, and inspection certificates from the local or international authorities may be required.

3. **Drug Master File (DMF)**
   - Comprehensive information about the Active Pharmaceutical Ingredient (API) manufacturing process, quality, and specifications.

4. **Stability Data**
   - Stability studies under climatic conditions specific to the Middle East (Zone IVb) are critical.

5. Labelling and Packaging

- Must comply with local language requirements (e.g., Arabic labeling).
- Clear instructions for use, storage, and warnings are essential.

3. Dossier Filing Requirements

The dossier format and submission processes generally align with the **Common Technical Document (CTD)** format, although some countries may have specific variations. Key sections of the CTD include.

Module 1: Regional Administrative and Product Information

- Application form.
- Product samples and mock-ups.
- GMP certificate.
- Certificate of Pharmaceutical Product (CPP) as per WHO format.
- Bioequivalence study report.
- Arabic translation of key documents.

Module 2: Common Technical Document Summaries

- Summaries of quality, preclinical, and clinical data.

Module 3: Quality Information

- Details on the drug substance and drug product.
- Stability study data.
- Validation and batch analysis reports.

Module 4: Nonclinical Study Reports

- May not be required if bioequivalence data suffice.

Module 5: Clinical Study Reports

- Primarily focused on bioequivalence studies.

4. Country-Specific Aspects

GCC Countries

- Submission to the GCC-DR program can allow simultaneous approval in all GCC member states.

- Countries like Saudi Arabia and UAE may require additional documents specific to their markets.

Egypt

- Requires a **Local Clinical Trial** (in some cases).
- Stringent documentation of the API and formulation process.

Jordan

- Prioritizes products with a history of regulatory approval in the US/EU.
- Mandatory bioequivalence studies must be conducted at local or approved facilities.

Iran

- Requires comprehensive data on API sourcing and local testing.
- Follows a product registration and import permit system**.**

Iraq, Lebanon, and Others

- Limited harmonization; dossier formats may differ slightly.
- Political and economic factors can influence regulatory timelines.

5. Post-Approval Requirements

- **Pharmacovigilance:** Ongoing monitoring of adverse drug reactions is mandatory.
- **Renewal of Registration:** Typically required every 5 years.
- **Price Regulation:** Many Middle Eastern countries regulate drug prices, requiring approval of pricing structures.

6. Challenges in the Region

1. **Regulatory Variability**
   - Each country has its own specific guidelines and timelines, leading to complexities.
2. **Language Barriers**
   - Requirements for Arabic translations add to the submission complexity.
3. **Market-Specific Needs**
   - Some countries require local manufacturing or testing as part of the approval process.
4. **Climatic Zone IVb Stability**
   - Extended stability testing can be a time-consuming requirement.
5. **Bureaucratic Delays**
   - Lengthy approval timelines in some countries like Iraq and Egypt.

7. Key Considerations for Success

- Collaborate with local agents who understand the regulatory landscape.
- Prepare for stringent inspections and audits of manufacturing facilities.
- Stay updated with evolving regulations in the region.
- Invest in market-specific packaging and Arabic labeling early in the process.

By navigating these regulatory aspects effectively, manufacturers can successfully introduce generic products to the Middle Eastern market.

2. GENERIC DRUG PRODUCTS REGISTRATION PROCESS IN MIDDLE EAST COUNTRIES[4-17]

The regulatory approval process involves the following key stages.

1. **Pre-submission Preparation**
   - Manufacturers collect all required documentation, including a **Common Technical Document (CTD)** dossier, bioequivalence studies, and GMP certifications.
   - Conduct required studies like **bioequivalence** in line with local guidelines.
2. **Submission of Dossier**
   - Submit the CTD dossier to the relevant **national regulatory authority** or a regional authority such as the GCC-DR (Gulf Cooperation Council Drug Registration program).
3. **Dossier Evaluation**
   - Regulatory bodies evaluate the product dossier for compliance with technical and regulatory requirements, including:
     - Bioequivalence data.
     - Quality assurance for the drug substance and product.
     - Stability studies tailored for Zone IVb (hot and humid climates).
4. **Registration and Approval**
   - Upon successful evaluation, the product is registered, and marketing authorization is granted.
5. **Post-Approval Activities**
   - Continuous monitoring through pharmacovigilance**.**
   - Periodic renewals and compliance with local regulations.

2. Regulatory Requirements by Country/Region

A. GCC (Gulf Cooperation Council) Countries

The GCC-DR allows for **harmonized submission** to multiple member countries, reducing the regulatory burden. Key steps.

1. **Dossier Preparation**
   - Format: **CTD format** with additional GCC-specific requirements.
   - Key Documents
     - Bioequivalence studies (must be compliant with **EMA** or **FDA standards**).
     - Certificate of Pharmaceutical Product (CPP) issued by a reference country.
     - Stability data for Zone IVb conditions.
2. **Submission to the GCC Health Council**
   - Centralized submission allows approval in multiple GCC member states (e.g., Saudi Arabia, UAE, Kuwait).
   - Additional country-specific approvals may still be required.
3. **Evaluation Process**
   - Initial screening for completeness.
   - Detailed technical review of pharmaceutical quality, safety, and efficacy data.
4. **Approval Timeline:**
   - Approval can take 6-12 months depending on dossier quality and regulatory backlog.

B. Saudi Arabia (SFDA - Saudi Food and Drug Authority)

The **SFDA** is one of the most stringent regulatory bodies in the region.

1. **Online Registration**
   - Submit the application via the **Saudi Drug Registration (SDR)** platform.
2. **Key Requirements**
   - Local bioequivalence studies are preferred.
   - Arabic translation of key sections of the dossier.
   - Labeling must comply with SFDA guidelines, including Arabic text.
3. **Evaluation Process**
   - Includes an in-depth review of the bioequivalence study.
   - May involve facility inspections if the manufacturing site has not been previously approved by SFDA.
4. **Timeline**
   - 12-18 months.

C. UAE (Ministry of Health and Prevention - MOHAP)

1. **Pre-registration**
   - Obtain manufacturing site approval if the site is not previously approved by MOHAP.
2. **Dossier Submission**
   - Must comply with GCC CTD format.
   - Arabic labeling and additional country-specific packaging requirements are necessary.
3. **Review Process**
   - Involves verification of bioequivalence, stability studies, and quality compliance.
4. **Timeline**
   - 6-12 months.

D. Egypt (Egyptian Drug Authority - EDA)

Egypt has specific requirements for generic products.

1. **Registration Application**
   - Submission through the **eCTD platform** of the EDA.
   - Local testing and bioequivalence studies are required.
2. **Dossier Requirements**
   - Stability data in Zone IVb conditions.
   - Detailed information on APIs and excipients.
3. **Review and Approval**
   - The review process includes pharmacological, chemical, and clinical data evaluation.
4. **Timeline**
   - Approval can take 12-18 months.

E. Jordan (Jordan Food and Drug Administration - JFDA)

1. **Submission**
   - Submit an **eCTD** dossier via the JFDA online portal.
   - Include bioequivalence studies conducted in an accredited facility.
2. **Evaluation Process**
   - Focus on the bioequivalence and stability data.
   - Requires proof of product registration in a reference country like the US or EU (optional for some cases).
3. **Timeline**
   - Typically 6-12 months.

F. Iran (Iran Food and Drug Administration - IFDA)

1. **Pre-Registration**
   - Requires local agent collaboration.
   - Obtain prior approval for the manufacturing site.
2. **Key Requirements**
   - API information and GMP compliance certificates.
   - Translation of the entire dossier into **Farsi**.
3. **Review Process**
   - Includes on-site inspections and quality testing.
4. **Timeline**
   - 12-24 months.

G. Iraq, Lebanon, and Other Middle Eastern Countries

1. **Iraq**
   - Requires a detailed **stability report** for Zone IVb.
   - Approval may take up to 2 years due to political and economic challenges.
2. **Lebanon**
   - Requires a Certificate of Pharmaceutical Product (CPP) and GMP certification.
   - Submission must comply with the Ministry of Public Health's guidelines

3. Challenges in the Approval Process

1. **Regulatory Variability**
   - Differences in requirements between countries lead to complexities.
2. **Language and Translation**
   - Arabic translations of labels and documents are mandatory in most countries.
3. **Extended Timelines**
   - Approval timelines are often prolonged due to regulatory backlog.
4. **Bioequivalence Studies**
   - Some countries require local bioequivalence studies, adding cost and time.

4. Key Tips for Successful Approval

1. **Understand Country-Specific Guidelines**
   - Stay updated on the latest regulations in each country.
2. **Invest in Bioequivalence Studies**
   - Ensure studies meet local standards and international guidelines.

3. **Collaborate with Local Agents**
   - Local agents or distributors can help navigate regulatory hurdles.
4. **Plan for Arabic Labeling**
   - Integrate local language and packaging requirements early in the process.

By adhering to the respective regulatory guidelines, generic drug manufacturers can successfully obtain approval and access the growing pharmaceutical markets in the Middle East.

3. CONCLUSION

The regulatory approval process and dossier filing for generic products in the Middle East are shaped by diverse regulatory frameworks and country-specific requirements. While many countries, especially in the GCC region, strive for harmonization through initiatives like the GCC-DR, manufacturers must address unique local demands, including language, packaging, and stability studies tailored to Zone IVb conditions. Key steps include robust bioequivalence studies, GMP-compliant manufacturing, and thorough preparation of CTD-format dossiers. Navigating these processes requires an understanding of regional regulations, collaboration with local agents, and attention to market-specific needs. Despite challenges such as regulatory variability and extended timelines, the growing demand for affordable healthcare in the Middle East offers significant opportunities for generic pharmaceutical manufacturers who can efficiently meet the regulatory requirements.

4. REFERENCES

1. Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use (ICH M4) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality (ICH M4Q).
2. The Common Technical Document for the Registration of Pharmaceuticals for HumanUse: Safety (ICH M4S).
3. The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Efficacy (ICH M4E) together with the complementary ICH Questions and Answers documents for the above mentioned guidelines.
4. Pan American Health Organization. Quality Assurance of Pharmaceuticals: A Compendium of Guidelines and Related Materials. 2nd ed. Washington, D.C.: Pan American Health Organization; 2007 [cited 2023 Apr 24]. Available from: https://iris.paho.org/bitstream/handle/10665.2/53793/9789275123447_eng.pdf?sequenc

5. Pan American Health Organization. Quality Control of Medicines [Internet]. Washington, D.C.: Pan American Health Organization; [cited 2023 Apr 24]. Available from: https://www.paho.org/en/topics/quality-control-medicines
6. Test Pharma Biz. Latam continues to lure global pharma industry [Internet]. [cited 2023 Apr 24]. Available from: https://test.pharmabiz.com/chronicle%20specials/ latamcontinues-to-lure-global-pharma-industry-90494
7. Market Data Forecast. Latin America Generic Drugs Market | Industry Analysis, Size, Share, Growth, Trends and Forecast 2019-2024 [Internet]. [cited 2023 Apr 24]. Available from: https://www.marketdataforecast.com/market-reports/latin-america-generic-drugsmarket
8. World Bank. Pharmaceuticals in Latin America and the Caribbean: Players, Access, and Innovation across Diverse Models [Internet]. [cited 2023 Apr 24]. Available from: https://documents1.worldbank.org/curated/en/766131641877985994/pdf/Pharmaceuticals in-Latin-America-and-the-Caribbean-Players-Access-and-Innovation-Across-DiverseModels.pdf
9. Patent Trademark Blog. Latin America patent problem and solution approach [Internet]. [cited 2023 Apr 24]. Available from: https://www.patenttrademarkblog.com/latin-americapatent-problem-and-solution-approach/
10. Department of Commerce, Government of India. Electronic Data Interchange (EDI) [Internet]. [cited 2023 Apr 24]. Available from: http://commerce.nic.in/eidb/Default.asp
11. Modern Pharma. Exporting to CIS, African, and Latam Countries: Tapping the Regulatory Benefits [Internet]. [cited 2023 Apr 24]. Available from: http://modernpharma.in/specials/pharma-export-regulations/exporting-to-cis-african-andlatam-countries-tapping-the-regulatory-benefits/3657.html
12. Brahmaiah Bonthagarala, Regulatory Requirements for Registration of Generic Drugs in "BRICS" Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, November-December 2016; 6(6): 20-39.
13. Brahmaiah Bonthagarala,Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic Goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, November-December 2016; 6(6): 144-157.
14. Brahmaiah Bonthagarala,Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, November-December 2016; 6(6): 1-19.

15. Brahmaiah Bonthagarala, Regulatory Requirements for Marketing of Generic Drugs in USA,International Journal of Pharmaceutical Research and Bio-Science, ISSN: 2277-8713, IJPRBS, 2017; 6(2): 178-195.
16. Brahmaiah Bonthagarala,Guidelines for bioavailability and bioequivalence studies: A Review, The Pharma Innovation Journal, 2018; 7(7): 661-666, ISSN (E): 2277- 7695.
17. Brahmaiah Bonthagarala *et al,* Generic Drug Registration and Regulatory Requirements in European Countries, World Journal of Pharmaceutical Research, 2018; 7(16): 800-815.